CIMA Labs
This article was originally published in The Tan Sheet
Executive Summary
Royalties and manufacturing revenues from Wyeth's Alavert expected to be major contributor to sales growth for fast-dissolve technology firm in 2003. Loratadine product "should end up this year [contributing] about 10% of our total revenues," President & CEO John Seibert, PhD, said during Feb. 20 analysts call. He noted Wyeth is "looking at this as the largest OTC product introduction in their history, and these are the people that brought you Advil." CIMA signed an exclusive supply agreement with Wyeth last June; Alavert employs CIMA's DuraSolv technology (1"The Tan Sheet" July 22, 2002, In Brief). Seibert estimated OTCs using CIMA technology account for 25% to 30% of the firm's revenues. CIMA's Q4 sales grew 68.5% to $15.5 mil., while annual sales rose 45.6% to $46.6 mil...
You may also be interested in...
Wyeth OTC loratadine “approvable”
FDA deems firm's application for Alavert, an OTC version of Schering-Plough's Claritin Reditabs (loratadine), approvable July 3. Alavert will employ CIMA Labs' DuraSolv technology; CIMA announced an exclusive license, supply agreement with Wyeth June 27 ("1The Tan Sheet" July 1, 2002, p. 4). Wyeth filed an NDA under section 505(b)(2) in January; McNeil also filed a 505(b)(2) application in November. Schering sued both companies for patent infringement 2("The Tan Sheet" Feb. 4, 2002, p. 3)...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.